Company Filing History:
Years Active: 2011-2019
Title: Michela Silacci: Innovator in Biopharmaceuticals
Introduction
Michela Silacci is a prominent inventor based in Zurich, Switzerland. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic agents. With a total of 2 patents, her work focuses on addressing critical medical challenges.
Latest Patents
Michela's latest patents include groundbreaking inventions such as antibody-fynomer conjugates. This bi-specific fusion polypeptide comprises a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence that binds to the interleukin-6 receptor (IL-6R). This innovative fusion polypeptide can bind to both IL-17a and IL-6R, thereby suppressing, reducing, decreasing, inhibiting, or blocking the activities of both IL-17a and IL-6R. Another notable patent involves antibodies against Tenascin-C, which are specific binding members against the extracellular matrix protein tenascin-C. This includes scFv antibody molecules targeting domain A1, domain C, and domain D of tenascin-C. These anti-tenascin-C specific binding members can be conjugated with labels, cytotoxic molecules, or cytokines, and are particularly useful in the diagnosis and treatment of cancer.
Career Highlights
Throughout her career, Michela has worked with esteemed companies such as Philogen S.p.a. and Mitsubishi Tanabe Pharma Corporation. Her expertise and innovative approach have positioned her as a key player in the biopharmaceutical industry.
Collaborations
Michela has collaborated with notable professionals in her field, including Simon Brack and Dario Neri. These partnerships have further enhanced her research and development efforts.
Conclusion
Michela Silacci's contributions to biopharmaceuticals through her innovative patents and collaborations highlight her as a leading inventor in the industry. Her work continues to pave the way for advancements in medical treatments.